Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$20.05 – $24.75
0% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $24.17B | $26.56B | $29.82B | $27.05B | $28.29B | $31.83B | $34.76B | $34.97B |
| Cost of revenue | $13.12B | $14.10B | $15.10B | $13.47B | $14.88B | $17.33B | $18.61B | $18.32B |
| Gross profit | $11.05B | $12.46B | $14.72B | $13.58B | $13.41B | $14.49B | $16.15B | $16.65B |
| Gross margin | 45.7% | 46.9% | 49.4% | 50.2% | 47.4% | 45.5% | 46.5% | 47.6% |
| R&D | $691.0M | $762.0M | $1.03B | $851.0M | $1.19B | $1.70B | $1.43B | $1.45B |
| Operating income | −$284.0M | $2.37B | $4.78B | $4.37B | $3.63B | $3.74B | $2.85B | $4.19B |
| EBITDA | $1.60B | $4.48B | $6.42B | $6.15B | $5.70B | $5.91B | $5.31B | $6.44B |
| Net income | −$967.0M | $1.22B | $3.24B | $2.97B | $2.49B | $2.41B | $1.64B | $2.26B |
| Net margin | -4.0% | 4.6% | 10.9% | 11.0% | 8.8% | 7.6% | 4.7% | 6.5% |
| EPS (diluted) | -3.55 | 4.49 | 11.89 | 10.90 | 9.15 | 8.86 | 6.01 | 8.29 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $34.7B | $11.50 | $11.34–$12.02 | 1 |
| 2027 | $36.4B | $13.19 | $13.01–$13.79 | 1 |
| 2028 | $38.1B | $14.74 | $14.54–$15.41 | 1 |
| 2029 | $42.1B | $16.33 | $16.11–$17.08 | 1 |
Forward consensus · source: Financial Modeling Prep
GETINGE AB SHS B
No one on the platform currently holds GNGBF.
No tracked institution reports a position in GNGBF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-04-23 | $4.7500 | 2026-04-28 |
| 2025-04-24 | $4.6000 | 2025-04-29 |
| 2024-04-23 | $4.4000 | 2024-04-29 |
No one on the platform has traded GNGBF yet.
| $2.5B |
| — |
| CLCGYClicks Group Limited | $28.09 | +0.52% | $3.3B | — |
| CSMYFCOSMOS Pharmaceutical Corporation | $37.06 | +0.00% | $2.9B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 3.7× earnings vs its 2.7× historical median P/E.
Fair value ≈ $14.84 · price $20.05 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.